A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: VH3810109
DRUG: Cabotegravir
DRUG: Standard of care (SOC)
BIOLOGICAL: rHuPH20

Sponsor

ViiV Healthcare